According to the data from Insight Health, for 92% of the 84,000 pharmaceutical products available, prices will be the same as last month, while 4.4% of them will become cheaper and 3.8% more expensive.
Despite price stability, the health insurance companies have incurred a rise in their pharmaceutical spending because of the ageing population, the improved treatment of national diseases such as hypertension, and the availability of new vaccines.